Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levopropranolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 9/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 6/20 | 1.00 |
| ▸ | NR2E1 | Q9Y466 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | HTR2B | P41595 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | SCN1A | P35498 | 2/20 | 1.00 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propranolol SCHEMBL10537386 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL1561135 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL12264958 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Dexpropranolol SCHEMBL29577201 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Levopropranolol SCHEMBL3956 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL3955 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Dexpropranolol SCHEMBL25255 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL6511347 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL22291223 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL20486000 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1CYP2D6ADRB3NR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4165142-B1 | Y2O3:RE NANOPARTICLES | SEABOROUGH IP I B V (NL) | 2025-03-12 | — | — | EP | claimed |
| US-20240358659-A1 | Uses of Propranolol for Managing Viral Infections | UNIV EMORY (US) | 2024-10-31 | — | — | US | claimed |
| CN-117731779-A | Use of Lipin1 inhibitors for the prevention or treatment of viral infections | 北京大学 | 2024-03-22 | — | — | CN | claimed |
| EP-3880386-B1 | COMPOSITION FOR 3D PRINTING | NANOE (FR) | 2024-01-03 | — | — | EP | claimed |
| EP-3726562-B1 | AMBIENT IONIZATION MASS SPECTROMETRY IMAGING PLATFORM FOR DIRECT MAPPING FROM BULK TISSUE | MICROMASS LTD (GB) | 2023-12-20 | — | — | EP | claimed |
| US-11819535-B2 | Composition and methods for regulating extracellular matrix accumulation | UNIVERSITY HEALTH NETWORK (CA) | 2023-11-21 | — | — | US | claimed |
| WO-2023198107-A1 | PREVENTION AND TREATMENT OF VIRAL INFECTION | PEKING UNIVERSITY (CN) | 2023-10-19 | — | — | WO | claimed |
| EP-3824883-B1 | NOVEL COMPOSITION FOR PLASTER BASE MATERIAL IN TAPE PREPARATION | MEDRX CO LTD (JP) | 2023-08-02 | — | — | EP | claimed |
| EP-4203929-A1 | METHODS AND COMPOSITIONS FOR TREATING HEART CONDITIONS | Lueninghoener, Catherine (US) | 2023-07-05 | — | — | EP | claimed |
| CN-115843246-A | Methods and compositions for treating hemangiomas | 吉利斯麦金德研究院 | 2023-03-24 | — | — | CN | claimed |
| US-20230090708-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMANGIOMA | MASSEY VENTURES LIMITED (NZ) | 2023-03-23 | — | — | US | claimed |
| WO-2023034282-A1 | USES OF PROPRANOLOL FOR MANAGING VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2023-03-09 | — | — | WO | claimed |
| EP-3853334-B1 | CONCENTRATES CONTAINING POLYSILOXANES STABLE UNDER STORAGE CONDITIONS AND THEIR USE PREFERABLY IN TEXTILE CARE COMPOSITIONS | EVONIK OPERATIONS GMBH (DE) | 2022-12-14 | — | — | EP | claimed |
| EP-4096648-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMANGIOMA | Gillies Mcindoe Research Institute (NZ) | 2022-12-07 | — | — | EP | claimed |
| EP-4087469-A1 | DEVICES AND METHODS FOR TREATING CANCER AND CARDIAC WASTING | Nazzano Devices Limited (IE) | 2022-11-16 | — | — | EP | claimed |
| EP-4051630-A1 | METHOD FOR PRODUCING A HYDROGEN-GENERATING FUEL, HYDROGEN-GENERATING FUEL OBTAINED, METHOD FOR PRODUCING HYDROGEN FROM THE FUEL, DEVICE FOR CARRYING OUT THE PRODUCTION METHOD, METHOD FOR OPERATING THE DEVICE, AND HYDROGEN-BASED FUEL OBTAINED BY MEANS OF THE HYDROGEN PRODUCTION METHOD | Prodose (FR) | 2022-09-07 | — | — | EP | claimed |
| EP-2313114-B1 | A DRUG POWDER FOR INHALATION ADMINISTRATION AND A PROCESS THEREOF | UNIV DEGLI STUDI DI PARMA (IT) | 2022-03-23 | — | — | EP | claimed |
| WO-2022051381-A1 | METHODS AND COMPOSITIONS FOR TREATING HEART CONDITIONS | LUENINGHOENER CATHERINE (US) | 2022-03-10 | — | — | WO | claimed |
| US-12611399-B2 | Movement disorders | Definium Therapeutics US, Inc. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-3941195-A1 | PHOTOAFFINITY PROBES | PROMEGA CORPORATION (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230090708-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMANGIOMA | AGTR2, AGTR1, AGT | ADRB2 7/4885ADRB1 15/4885CYP2D6 2158/4885 |
| US-12611399-B2 | Movement disorders | SNCA, SLC6A3, DRD2 | ADRB2 116/4885ADRB1 156/4885CYP2D6 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.